BC Platforms introduced that it had been chosen as a key accomplice in a European Fee (EC) challenge.
Underneath the EC’s Horizon Europe program, Helsinki College Hospital (HUS), has been awarded a contract to steer a consortium challenge of EURO 7 million (approx. USD 7.2 million), referred to as ONCOVALUE. BCP will work carefully with HUS as a key supply accomplice on this main EC challenge.
ONCOVALUE is an Synthetic Intelligence-based framework which assesses, in real-time, the real-life effectiveness of novel most cancers therapies. It does this by standardising knowledge processing in hospitals enabling them to effectively measure the cost-effectiveness of latest most cancers therapies for Well being Expertise Evaluation (HTA) and regulatory functions.
BCP will assist in core points of the challenge, together with creating the technical structure and offering the information evaluation, to make sure this expertise can rework unstructured affected person knowledge from medical notes and pictures into structured knowledge and real-world proof (RWE) that clinicians can use in therapy administration and with well being regulatory and HTA our bodies
Tero Silvola, CEO of BC Platforms, stated, “This newest partnership with ONCOVALUE is a part of our quickly increasing Trusted Collaborative Atmosphere answer. I’m proud our subtle healthcare knowledge administration and analytics merchandise have been recognised by this vital, four-year, Horizon Europe challenge. By opening the door to widespread regulatory and HTA integration of real-world knowledge, ONCOVALUE ought to result in higher, extra environmentally sustainable therapies, applied sciences, and digital options for most cancers care.”
Johanna Mattson, HUS’s Senior Medical Director in Oncology, stated, “ONCOVALUE goals to develop novel AI-based instruments to automate the gathering and analytics of medical knowledge. This may contribute to the elevated cost-effectiveness and sustainability of European most cancers care. Systematic assortment and analysis of affected person reported outcomes ought to result in improved well being and well-being and will scale back the rising international burden of most cancers therapy.”
The ONCOVALUE consortium includes of 11 establishments and firms in Finland, The Netherlands, Denmark, Portugal, and Italy. Over the four-year challenge span, yearly round 40,000 European sufferers will take part from hospitals within the consortium.